Coffey Robert J, Washington Mary Kay, Corless Christopher L, Heinrich Michael C
Department of Medicine, Vanderbilt University Medical Center and Nashville Veterans Affairs Medical Center, Nashville, Tennessee, USA.
J Clin Invest. 2007 Jan;117(1):70-80. doi: 10.1172/JCI30491.
Ménétrier disease and gastrointestinal stromal tumors (GISTs) are hyperproliferative disorders of the stomach caused by dysregulated receptor tyrosine kinases (RTKs). In Ménétrier disease, overexpression of TGF-alpha, a ligand for the RTK EGFR, results in selective expansion of surface mucous cells in the body and fundus of the stomach. In GISTs, somatic mutations of the genes encoding the RTK KIT (or PDGFRA in a minority of cases) result in constitutive kinase activity and neoplastic transformation of gut pacemaker cells (interstitial cells of Cajal). On the basis of the involvement of these RTKs in the pathogenesis of these disorders, Ménétrier disease patients have been effectively treated with a blocking monoclonal antibody specific for EGFR and GIST patients with KIT and PDGFRA tyrosine kinase inhibitors.
梅内特里耶病和胃肠道间质瘤(GISTs)是由受体酪氨酸激酶(RTKs)失调引起的胃部过度增殖性疾病。在梅内特里耶病中,RTK表皮生长因子受体(EGFR)的配体转化生长因子-α(TGF-α)的过表达导致胃体和胃底表面黏液细胞的选择性扩张。在胃肠道间质瘤中,编码RTK KIT的基因(少数情况下为PDGFRA)的体细胞突变导致组成性激酶活性和肠道起搏细胞( Cajal间质细胞)的肿瘤转化。基于这些RTKs参与这些疾病的发病机制,梅内特里耶病患者已用针对EGFR的阻断性单克隆抗体有效治疗,胃肠道间质瘤患者则用KIT和PDGFRA酪氨酸激酶抑制剂治疗。